ATRCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
AtriCure, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026
$55.53−0.54 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $2.71B
- P/E (TTM)
- 264.4
- Dividend yield
- –
Share price
+$18.37 (+49.43%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
AtriCure, Inc. grew revenue 13.9% to $569.62M over the twelve months to Jun 30, 2026. Free cash flow was $53.11M, up 110.0% from a year earlier.
Revenue
$569.62M
+13.9% vs. a year earlier
Operating income
$12.89M
TTM Q2 2026
Free cash flow
$53.11M
+110.0% vs. a year earlier
EPS, diluted
$0.21
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.71B
- P/E ratio
- 264.4
- Price to sales
- 4.76
- Price to book
- 5.25
- Dividend yield
- –
- Free cash flow yield
- 1.96%
Fundamentals
- Revenue
- $569.62M
- Net income
- $10.55M
- EPS, diluted
- $0.21
- Free cash flow
- $53.11M
- Book value per share
- $10.57
- Diluted shares
- 49M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$569.62M+13.9% YoY
Gross profit
$434.61M+16.4% YoY
Operating income
$12.89M
Net income
$10.55M
EPS, diluted
$0.21
Free cash flow
$53.11M+110.0% YoY
Reported periodTrailing twelve months